Your browser doesn't support javascript.
loading
Spot specimen testing with GeneXpert MTB/RIF results compared to morning specimen in a programmatic setting in Cotonou, Benin.
Massou, Faridath; Fandohan, Merlin; Wachinou, Ablo Prudence; Agbla, Schadrac Christin; Agodokpessi, Gildas; Rigouts, Leen; de Jong, Bouke Catherine; Affolabi, Dissou.
Afiliação
  • Massou F; National Tuberculosis Program, NTP, Cotonou, Benin. abenimas@gmail.com.
  • Fandohan M; Supranational Reference Laboratory for Tuberculosis of Cotonou, Cotonou, Benin. abenimas@gmail.com.
  • Wachinou AP; National Tuberculosis Program, NTP, Cotonou, Benin.
  • Agbla SC; National Tuberculosis Program, NTP, Cotonou, Benin.
  • Agodokpessi G; London School of Hygien and Tropical Medicine, London, UK.
  • Rigouts L; University of Liverpool, Liverpool, UK.
  • de Jong BC; National Tuberculosis Program, NTP, Cotonou, Benin.
  • Affolabi D; Institute of Tropical Medicine, Antwerp, Belgium.
BMC Infect Dis ; 21(1): 979, 2021 Sep 20.
Article em En | MEDLINE | ID: mdl-34544371
ABSTRACT

BACKGROUND:

The diagnosis of tuberculosis (TB) using smear microscopy has been based on testing two specimens one spot and one early morning sputa. Recently, the World Health Organization (WHO) has recommended to replace, whenever possible, microscopy with GeneXpert® MTB/RIF performed on a single specimen. However, as the bacterial load is higher in early morning specimens than in spot specimens, one could expect lower sensitivity of GeneXpert® MTB/RIF performed only on spot specimens. In this study, we compared results of GeneXpert® MTB/RIF on spot specimens versus early morning specimens, under programmatic conditions in Cotonou, Benin.

METHODS:

From June to September 2018, all sputa received from presumptive TB patients at the Supranational Reference Laboratory for Tuberculosis of Cotonou were included in the study. From each patient, two specimens were collected (one spot and one early morning) and GeneXpert® MTB/RIF was performed on both specimens.

RESULTS:

In total, 886 participants were included in the study, of whom 737 provided both sputa and 149 (16.8%) gave only the spot specimen. For the 737 participants who provided both sputa, GeneXpert® MTB/RIF was positive for both specimens in 152 participants; for three participants GeneXpert® MTB/RIF was positive on spot specimen but negative on morning specimen while for another three, the test was positive on morning specimen but negative on spot specimen. The overall percentage of agreement was excellent (99.2%) with a positive and negative percent agreement greater than 98%.

CONCLUSION:

For TB diagnosis under programmatic conditions in Cotonou, GeneXpert® MTB/RIF in spot specimens gave similar results with the test in morning specimens. Performing GeneXpert® MTB/RIF in both specimens did not significantly increase the number of cases detected. To avoid losing patients from the diagnostic cascade, it is preferable to test sputa produced at the time of the first visit at the health center.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 / 3_ND Base de dados: MEDLINE Assunto principal: Mycobacterium tuberculosis Tipo de estudo: Diagnostic_studies Limite: Humans País/Região como assunto: Africa Idioma: En Revista: BMC Infect Dis Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 / 3_ND Base de dados: MEDLINE Assunto principal: Mycobacterium tuberculosis Tipo de estudo: Diagnostic_studies Limite: Humans País/Região como assunto: Africa Idioma: En Revista: BMC Infect Dis Ano de publicação: 2021 Tipo de documento: Article